DOCSLIB.ORG

LNG-IUS) in Patients Affected by Menometrorrhagia, Dysmenorrhea and Adenomimyois: Clinical and Ultrasonographic Reports

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LNG-IUS) in Patients Affected by Menometrorrhagia, Dysmenorrhea and Adenomimyois: Clinical and Ultrasonographic Reports European Review for Medical and Pharmacological Sciences 2021; 25: 3432-3439 The treatment with Levonorgestrel Releasing Intrauterine System (LNG-IUS) in patients affected by menometrorrhagia, dysmenorrhea and adenomimyois: clinical and ultrasonographic reports F. COSTANZI, M.P. DE MARCO, C. COLOMBRINO, M. CIANCIA, F. TORCIA, I. RUSCITO, F. BELLATI, A. FREGA, G. COZZA, D. CASERTA Department of Surgical and Medical Sciences and Translational Medicine, Sant’Andrea University Hospital, Sapienza University of Rome, Rome, Italy Abstract. – OBJECTIVE: Adenomyosis is p=0.025; p=0.014). The blood loss decreased the consequence of the myometrial invasion significantly in both the cohorts (p<0.001) and by endometrial glands and stroma. Transvag- particularly in adenomyotic patients. Pain relief inal ultrasonography plays a decisive role in was observed in all the patients (p<0.001). the diagnosis and monitoring of this patholo- CONCLUSIONS: LNG-IUS can be considered gy. Our study aims to evaluate the efficacy of an effective treatment for managing symptoms LNG-IUS (Levonorgestrel Releasing Intrauter- and improving uterine morphology. ine System) as medical therapy. We analyzed both clinical symptoms and ultrasonograph- Key Words: ic aspects of menometrorrhagia and dysmen- Benign disease of uterus, Dysmenorrhea, Gyne- orrhea in patients with adenomyosis and the cologic imaging, Leiomyomas of the uterus/adeno- control group. myosis. PATIENTS AND METHODS: A prospective co- hort study was carried out on 28 patients suf- fering from symptomatic adenomyosis treat- ed with LNG-IUS. Adenomyosis was diagnosed Introduction through transvaginal ultrasonography by an ex- pert sonographer. A control group of 27 symp- Adenomyosis is a benign gynecological dis- tomatic patients (menorrhagia and dysmenor- ease with a large variety of clinical manifestation; rhea) without a transvaginal ultrasonograph- the most frequent include menorrhagia, metror- ic diagnosis of adenomyosis was treated in the rhagia, dysmenorrhea and chronic pelvic pain1. same way. The two cohorts were compared to Patients can also experience dyspareunia and the efficacy of LNG-IUS on menorrhagia and 2,3 dysmenorrhea. Patients are evaluated at the infertility . Its pathogenesis is still unknown, al- time of LNG-IUS insertion and six months after though many theories have been considered over for: increased uterine volume, globulous uter- the years2. Adenomyosis is histologically defined ine morphology, uterine symmetry, alterations as the ectopic presence of endometrial glands in the junctional zone, heterogeneous myome- and stroma in the myometrium, with consequent trial texture, presence of myometrial cysts, hy- hyperplasia and hypertrophy of the smooth mus- perechogenic lines crossing the myometrium, 4 adenomyomas, menstrual blood loss and dys- cle . Nowadays, a definite diagnosis is still made menorrhea. on a pathological analysis performed on uterine RESULTS: After six months, the uterine vol- specimens. ume decreased significantly in both cohorts Nevertheless, non-invasive image techniques, (p=0.005; p=0.005). Furthermore, uterine sym- such as transvaginal ultrasound (TVS) and mag- metry, visibility of the junctional zone, hetero- netic resonance imaging (MRI), have proven geneity of myometrial texture, presence of myo- helpful in the preoperative diagnosis of adeno- metrial cysts, hyperechogenic lines and adeno- 5-7 8,9 myomas improved in patients affected by ade- myosis disease . Authors who compared the nomyosis (p>0.001; p>0.001; p>0.001; p=0.014; results obtained from TVS and MRI with those 3432 Corresponding Author: Flavia Costanzi, MD; e-mail: [email protected] Role of Levonorgestrel Releasing Intrauterine System (LNG-IUS): clinical reports obtained from histopathology have noticed that Patients and Methods MRI and TVS’s diagnostic efficiency was almost in line. TVS is considered the first choice of im- Patients age modality when investigating adenomyosis; From May 2017 to June 2018 – after obtaining however, MRI may be helpful in increasing the approval of the Ethics Committee (Protocol No. diagnostic performance when TVS provides in- 23957) – 55 patients between 35 and 50 years old definite findings or when dealing with complex with menorrhagia and heavy menstrual bleeding cases with the coexistence of other abnormal- were enrolled from the Gynecology department ities (e.g., myomas and severe endometriosis)10 of Department of Surgical and Medical Sciences sonographic diagnosis of adenomyosis is made and Translational Medicine, Sant’Andrea Uni- when at least three of the following signs are versity Hospital, Sapienza University of Rome, found: increased uterine volume, globulous uter- Rome, Italy. Twenty-eight patients were diag- ine morphology, uterine asymmetry, alterations nosed with adenomyosis, whereas 27 patients did in the junctional zone, heterogeneous myometri- not meet the criteria to be diagnosed with the al texture, myometrial cysts and hyperechogenic same pathology. All included patients had mod- lines crossing the myometrium. To date, there erate or severe symptoms of dysmenorrhea and are not international guidelines for the clinical metrorrhagia. All patients were candidates for and surgical management of the pathology. Hys- therapy with LNG-IUS due to the presence of terectomy is a definite treatment of symptomatic symptoms. patients, but plenty of conservative medical and surgical options can be considered to treat ad- Inclusion criteria were: enomyosis. Adenomyosis, in childbearing age, – no hormonal therapies in the previous six could be managed with a less invasive approach months; like medical therapy or conservative surgery. – no previous diagnosis PID; The results obtained from conventional surgery – no previous or current gynecological tumors are effective for symptom control. Improve ab- (cervix, uterus, ovaries); dominal pain, abnormal uterine bleeding and – did not undergo surgeries of the genital area. improve fertility are the main results of this type of surgery11. Levonorgestrel Releasing Exclusion criteria were: Intrauterine System (LNG-IUS) represents one – could not be treated using LNG-IUS of the medical alternatives in the treatment of – received hormonal therapies in the previous six adenomyosis. This device has been approved months; in Europe as a contraceptive method in 1990; – had/ was having PID; more recently, it has been used to manage men- – had gynecological tumors (cervix, uterus, ova- orrhagia and dysmenorrhea12, abnormal uterine ries); bleeding (AUB), endometrial hyperplasia, ad- – underwent surgeries of the genital area; enomyosis13 uterine fibroids and as a progestin – pregnancy. component in postmenopausal hormone thera- py14. The use of LNG-IUS for five years duration Adenomyosis was diagnosed by an expert so- is motivated by the inhibition of the endometrial nographer when at least 3 of the following signs proliferation induced by the drug, which leads were found at the transvaginal ultrasound (TVS): to a positive impact on dysmenorrhea and heavy – Increased uterine volume; menstrual bleeding. – Globulous uterine morphology; Moreover, because of the local administration – Uterine asymmetry; of the drug (1000 ng/mL intrauterine vs. <0.2 – Alterations in the junctional zone; ng/mL plasmatic), the device is characterized – Heterogeneous myometrial texture; by low metabolic side effects15. Indeed, patients – Presence of myometrial cysts; show excellent tolerance and good compliance – Hyperechogenic lines crossing the myometri- in the majority of cases16,17. With these premises, um and adenomyomas. the objective of this pilot study is to evaluate the efficacy of LNG-IUS as medical therapy to treat All patients were asked for their medical histo- both clinical symptoms (dysmenorrhea and heavy ry and symptoms, including menometrorrhagia, menstrual bleeding in particular) and ultrasono- dysmenorrhea, chronic pelvic pain and dyspareu- graphic aspects of adenomyosis. nia. All patients were adequately informed and 3433 F. Costanzi, M.P. De Marco, C. Colombrino, M. Ciancia, F. Torcia, et al provided written informed consent for inclusion Statistical Analysis in the study and implantation of LNG-IUS. They All data were statistically analyzed using were also asked for providing the results of a the non-parametric Wilcoxon signed-rank test PAP-smear and a vaginal smear done respective- (not-continuous variables) or ANOVA 2x2x2 ly within the previous year and the last month. (continuous variables) using SPSS 24.0 (Statis- They underwent LNG-IUS implantation between tical Product and Service Solution; IBM Corp., the 5th and seventh day of the menstrual cycle. Armonk, NY, USA). Differences were considered Patients were divided into two cohorts, “adeno- significant at a p-value <0.05. First, a Kolmogor- myosis” and “not-adenomyosis”. Both the cohorts ov-Smirnov test was made to study the distribu- were followed up clinically over time and then tion of data. Parametric tests and non-parametric compared to study the efficacy in the absolute tests were respectively conducted to investigate value of LNG-IUS on adenomyosis. the variables. Clinical Follow-Up Ultrasonographic parameters and symptoms Results were registered before starting the treatment and during the clinical follow-up. Follow-up Our study evaluated how parameters changed was conducted at 1, 3 and 6 months from the in 6 months, both in each cohort and between the implantation. Visits were made by the same so- two cohorts. General characteristics of patients are
Load more

Recommended publications
  • The Male Reproductive System
    Management of Men’s Reproductive 3 Health Problems Men’s Reproductive Health Curriculum Management of Men’s Reproductive 3 Health Problems © 2003 EngenderHealth. All rights reserved. 440 Ninth Avenue New York, NY 10001 U.S.A. Telephone: 212-561-8000 Fax: 212-561-8067 e-mail: [email protected] www.engenderhealth.org This publication was made possible, in part, through support provided by the Office of Population, U.S. Agency for International Development (USAID), under the terms of cooperative agreement HRN-A-00-98-00042-00. The opinions expressed herein are those of the publisher and do not necessarily reflect the views of USAID. Cover design: Virginia Taddoni ISBN 1-885063-45-8 Printed in the United States of America. Printed on recycled paper. Library of Congress Cataloging-in-Publication Data Men’s reproductive health curriculum : management of men’s reproductive health problems. p. ; cm. Companion v. to: Introduction to men’s reproductive health services, and: Counseling and communicating with men. Includes bibliographical references. ISBN 1-885063-45-8 1. Andrology. 2. Human reproduction. 3. Generative organs, Male--Diseases--Treatment. I. EngenderHealth (Firm) II. Counseling and communicating with men. III. Title: Introduction to men’s reproductive health services. [DNLM: 1. Genital Diseases, Male. 2. Physical Examination--methods. 3. Reproductive Health Services. WJ 700 M5483 2003] QP253.M465 2003 616.6’5--dc22 2003063056 Contents Acknowledgments v Introduction vii 1 Disorders of the Male Reproductive System 1.1 The Male
    [Show full text]
  • Prolactin Level in Women with Abnormal Uterine Bleeding Visiting Department of Obstetrics and Gynecology in a University Teaching Hospital in Ajman, UAE
    Prolactin level in women with Abnormal Uterine Bleeding visiting Department of Obstetrics and Gynecology in a University teaching hospital in Ajman, UAE Jayakumary Muttappallymyalil1*, Jayadevan Sreedharan2, Mawahib Abd Salman Al Biate3, Kasturi Mummigatti3, Nisha Shantakumari4 1Department of Community Medicine, 2Statistical Support Facility, CABRI, 4Department of Physiology, Gulf Medical University, Ajman, UAE 3Department of OBG, GMC Hospital, Ajman, UAE *Presenting Author ABSTRACT Objective: This study was conducted among women in the reproductive age group with abnormal uterine bleeding (AUB) to determine the pattern of prolactin level. Materials and Methods: In this study, a total of 400 women in the reproductive age group with AUB attending GMC Hospital were recruited and their prolactin levels were evaluated. Age, marital status, reproductive health history and details of AUB were noted. SPSS version 21 was used for data analysis. Descriptive statistics was performed to describe the population, and inferential statistics such as Chi-square test was performed to find the association between dependent and independent variables. Results: Out of 400 women, 351 (87.8%) were married, 103 (25.8%) were in the age group 25 years or below, 213 (53.3%) were between 26-35 years and 84 (21.0%) were above 35 years. Mean age was 30.3 years with a standard deviation 6.7. The prolactin level ranged between 15.34 mIU/l and 2800 mIU/l. The mean and SD observed were 310 mIU/l and 290 mIU/l respectively. The prolactin level was high among AUB patients with inter-menstrual bleeding compared to other groups. Additionally, the level was high among women with age greater than 25 years compared to those with age less than or equal to 25 years.
    [Show full text]
  • Endometriosis for Dummies.Pdf
    01_050470 ffirs.qxp 9/26/06 7:36 AM Page i Endometriosis FOR DUMmIES‰ by Joseph W. Krotec, MD Former Director of Endoscopic Surgery at Cooper Institute for Reproductive Hormonal Disorders and Sharon Perkins, RN Coauthor of Osteoporosis For Dummies 01_050470 ffirs.qxp 9/26/06 7:36 AM Page ii Endometriosis For Dummies® Published by Wiley Publishing, Inc. 111 River St. Hoboken, NJ 07030-5774 www.wiley.com Copyright © 2007 by Wiley Publishing, Inc., Indianapolis, Indiana Published by Wiley Publishing, Inc., Indianapolis, Indiana Published simultaneously in Canada No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permit- ted under Sections 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400, fax 978-646-8600. Requests to the Publisher for permission should be addressed to the Legal Department, Wiley Publishing, Inc., 10475 Crosspoint Blvd., Indianapolis, IN 46256, 317-572-3447, fax 317-572-4355, or online at http:// www.wiley.com/go/permissions. Trademarks: Wiley, the Wiley Publishing logo, For Dummies, the Dummies Man logo, A Reference for the Rest of Us!, The Dummies Way, Dummies Daily, The Fun and Easy Way, Dummies.com, and related trade dress are trademarks or registered trademarks of John Wiley & Sons, Inc., and/or its affiliates in the United States and other countries, and may not be used without written permission.
    [Show full text]
  • Vaginitis and Abnormal Vaginal Bleeding
    UCSF Family Medicine Board Review 2013 Vaginitis and Abnormal • There are no relevant financial relationships with any commercial Vaginal Bleeding interests to disclose Michael Policar, MD, MPH Professor of Ob, Gyn, and Repro Sciences UCSF School of Medicine [email protected] Vulvovaginal Symptoms: CDC 2010: Trichomoniasis Differential Diagnosis Screening and Testing Category Condition • Screening indications – Infections Vaginal trichomoniasis (VT) HIV positive women: annually – Bacterial vaginosis (BV) Consider if “at risk”: new/multiple sex partners, history of STI, inconsistent condom use, sex work, IDU Vulvovaginal candidiasis (VVC) • Newer assays Skin Conditions Fungal vulvitis (candida, tinea) – Rapid antigen test: sensitivity, specificity vs. wet mount Contact dermatitis (irritant, allergic) – Aptima TMA T. vaginalis Analyte Specific Reagent (ASR) Vulvar dermatoses (LS, LP, LSC) • Other testing situations – Vulvar intraepithelial neoplasia (VIN) Suspect trich but NaCl slide neg culture or newer assays – Psychogenic Physiologic, psychogenic Pap with trich confirm if low risk • Consider retesting 3 months after treatment Trichomoniasis: Laboratory Tests CDC 2010: Vaginal Trichomoniasis Treatment Test Sensitivity Specificity Cost Comment Aptima TMA +4 (98%) +3 (98%) $$$ NAAT (like GC/Ct) • Recommended regimen Culture +3 (83%) +4 (100%) $$$ Not in most labs – Metronidazole 2 grams PO single dose Point of care – Tinidazole 2 grams PO single dose •Affirm VP III +3 +4 $$$ DNA probe • Alternative regimen (preferred for HIV infected
    [Show full text]
  • Gynecology Revised: 11/2013
    Emergency Medical Training Services Emergency Medical Technician – Paramedic Program Outlines Outline Topic: Gynecology Revised: 11/2013 21 questions on exam 8 from this outline • Menstruation - normal periodic discharge of blood, mucus, and cellular debris from uterus. The normal menstrual cycle lasts about 28 days. 25 to 60mL average flow. Flow lasts usually 4 to 6 days. Lining of the uterus is called endometrium. Onset of menses (menarche) begins around 12 years of age. Menopause starts at age 47 on average. But can range from 30 to 60 years of age. Estrogen stimulates endometrium to grow and increase in thickness. • Ovaries contain about 5 million cells to make oocytes (immature ova/eggs). At puberty 350,000 are present. In a lifetime the ovary will release 400 through menstruation • The release of the egg is termed ovulation. • The pituitary released FSH to stimulate the ovaries to produce estrogen. As a result of the estrogen builds up in blood stream just before ovulation the pituitary releases luteinizing hormone to initiate the release of eggs. • Up to seven days after ovulation (day 21) the uterus is ready to receive an embryo if fertilization has happened. • Recap: Day 14 ovulation. Up to day 21 fertilization window, day 22 thru 28 period if not pregnant. GYN emergencies are classified as: Non-traumatic • PID - infection entered the pelvis cavity. Most common causes are non-sterile exam equipment and if sexually transmitted is N. Gonorrhea and Chlamydia. Lower abdominal pain, hurts with sex, vaginal discharge and additional bleeding after period is over. Antibiotic therapy is needed. • Ovarian cyst - can be a bleeding/shock emergency.
    [Show full text]
  • Management of Primary Dysmenorrhea in Young Women with Frameless LNG-IUS
    Open Access Journal of Contraception Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Management of primary dysmenorrhea in young women with frameless LNG-IUS Dirk Wildemeersch1 Abstract: The objective of this paper is to discuss the potential advantages of intrauterine treat- Sohela Jandi2 ment with a frameless levonorgestrel (LNG)-releasing intrauterine system (IUS) in young women Ansgar Pett2 presenting with primary dysmenorrhea associated with heavy menstrual bleeding. The paper is Thomas Hasskamp3 based on clinical reports of 21 cases of primary and secondary dysmenorrhea treated with the frameless LNG-IUS. Three typical examples of young women between 16 and 20 years of age, 1Gynecological Outpatient Clinic and IUD Training Center, Ghent, who presented with moderate-to-severe primary dysmenorrhea associated with heavy menstrual Belgium; 2Gynecological Outpatient bleeding, are presented as examples. Following pelvic examination, including vaginal sonography, 3 Clinic, Berlin, Germany; GynMünster, a frameless LNG-IUS, releasing 20 µg of LNG/day, was inserted. The three patients developed Münster, Germany amenorrhea, or scanty menstrual bleeding, and absence of pain complaints within a few months. We conclude that continuous, intrauterine progestogen delivery could be a treatment of choice of this inconvenient condition. In addition, the good experiences with the frameless LNG-IUS in other studies suggests that the frameless design may be preferred over a framed LNG-IUS, as the absence of a frame, resulting in optimal tolerance, is particularly advantageous in these women. Keywords: heavy menstrual bleeding, contraception, FibroPlant, intrauterine system Video abstract Introduction In an epidemiologic study of an adolescent population, Klein and Litt reported a prevalence of dysmenorrhea of 59.7%.1 Of patients reporting pain, 12% described it as severe, 37% as moderate, and 49% as mild.
    [Show full text]
  • Epidemiology of Menstrual Disorders in Developing Countries: a Systematic Review
    BJOG: an International Journal of Obstetrics and Gynaecology DOI: 10.1046/j.1471-0528.2003.00012.x January 2004, Vol. 111, pp. 6–16 REVIEW Epidemiology of menstrual disorders in developing countries: a systematic review Introduction Information on the prevalence of menstrual complaints in the past three months was obtained in seven countries In developing countries, priority setting in the health (Table 1). These data permit cross national comparisons sector traditionally focuses on the principal causes of mor- in so far as similar questions with a similar time reference tality. More recently, the Global Burden of Disease approach were asked. However, no definitions were provided and incorporates assessment of morbidity and quality of life in considerable variation in the interpretation of questions identifying priorities. Yet, although investigations in various among individuals and across cultures is likely. developing countries reveal that women are concerned by Approximately a dozen subsequent surveys, including menstrual disorders, little attention is paid to understanding community-based, clinic-based and one national census, or ameliorating women’s menstrual complaints.1 Menstrual include some information on menstrual morbidities6–29 dysfunction, like other aspects of sexual and reproductive (Table 2). A few health surveys of special populations, health, is not included in the Global Burden of Disease such as factory workers in Vietnam17 and medical students estimates2,3 and, even as reproductive health programs in Venezuela,27,28 have also included relevant questions expand their focus to address gynaecologic morbidity, the on menstrual disorders. These surveys vary consider- utility of evaluating and treating menstrual problems is ably in the definition of and reference period for men- not generally considered.
    [Show full text]
  • Abnormal Uterine Bleeding: a Management Algorithm
    J Am Board Fam Med: first published as 10.3122/jabfm.19.6.590 on 7 November 2006. Downloaded from EVIDENCED-BASED CLINICAL MEDICINE Abnormal Uterine Bleeding: A Management Algorithm John W. Ely, MD, MSPH, Colleen M. Kennedy, MD, MS, Elizabeth C. Clark, MD, MPH, and Noelle C. Bowdler, MD Abnormal uterine bleeding is a common problem, and its management can be complex. Because of this complexity, concise guidelines have been difficult to develop. We constructed a concise but comprehen- sive algorithm for the management of abnormal uterine bleeding between menarche and menopause that was based on a systematic review of the literature as well as the actual management of patients seen in a gynecology clinic. We started by drafting an algorithm that was based on a MEDLINE search for rel- evant reviews and original research. We compared this algorithm to the actual care provided to a ran- dom sample of 100 women with abnormal bleeding who were seen in a university gynecology clinic. Discrepancies between the algorithm and actual care were discussed during audiotaped meetings among the 4 investigators (2 family physicians and 2 gynecologists). The audiotapes were used to revise the algorithm. After 3 iterations of this process (total of 300 patients), we agreed on a final algorithm that generally followed the practices we observed, while maintaining consistency with the evidence. In clinic, the gynecologists categorized the patient’s bleeding pattern into 1 of 4 types: irregular bleeding, heavy but regular bleeding (menorrhagia), severe acute bleeding, and abnormal bleeding associated with a contraceptive method. Subsequent management involved both diagnostic and treatment interven- tions, which often occurred simultaneously.
    [Show full text]
  • Too Much, Too Little, Too Late: Abnormal Uterine Bleeding
    Too much, too little, too late: Abnormal uterine bleeding Jody Steinauer, MD, MAS July, 2015 The Questions • Too much (& too early or too late) – Differential and approach to work‐up – Does she need an endometrial biopsy (EMB)? – Does she need an ultrasound? – How do I stop peri‐menopausal bleeding? – Isn’t it due to the fibroids? • Too fast: She’s hemorrhaging—what do I do? • Too little: A quick review of amenorrhea Case 1 A 46 yo G3P2T1 reports her periods have become 1. What term describes increasingly irregular and heavy her symptoms? over the last 6‐8 months. 2. Physiologically, what Sometimes they come 2 times causes this type of per month and sometimes there bleeding pattern? are 2 months between. LMP 2 3. What is the months ago. She bleeds 10 days differential? with clots and frequently bleeds through pads to her clothes. She occasionally has hot flashes. She also has diabetes and is obese. Q1: In addition to a urine pregnancy test and TSH, which of the following is the most appropriate test to obtain at this time? 1. FSH 2. Testosterone & DHEAS 3. Serum beta‐HCG 4. Transvaginal Ultrasound (TVUS) 5. Endometrial Biopsy (EMB) Terminology: What is abnormal? • Normal: Cycle= 28 days +‐ 7 d (21‐35); Length=2‐7 days; Heaviness=self‐defined • Too little bleeding: amenorrhea or oligomenorrhea • Too much bleeding: Menorrhagia (regular timing but heavy (according to patient) OR long flow (>7 days) • Irregular bleeding: Metrorrhagia, intermenstrual or post‐ coital bleeding • Irregular and Excessive: Menometrorrhagia • Preferred term for non‐pregnant bleeding issues= Abnormal Uterine Bleeding (AUB) – Avoid “DUB” ‐ dysfunctional uterine bleeding.
    [Show full text]
  • Selected Topics in WOMEN’S HEALTH
    www.bpac.org.nz keyword: womenshealth Selected topics in WOMEN’S HEALTH Laboratory investigation of amenorrhoea Polycystic ovary syndrome An overview of dysfunctional uterine bleeding Perimenopause and menopause Sexual dysfunction - loss of libido 8 | September 2010 | best tests Amenorrhoea Amenorrhoea is the absence of menstruation flow. It can Causes of primary amenorrhoea2 be classified as either primary or secondary,1 relative to menarche: ■ Hypergonadotropic hypogonadism/primary hypogonadism/gonadal failure: ■ Primary amenorrhoea: absence of menses by age 16 years in a female with appropriate development – Abnormal sex chromosomes e.g. Turner of secondary sexual characteristics; or absence syndrome of menses by age 13 years and no other pubertal – Normal sex chromosomes e.g. premature maturation2 ovarian failure ■ Secondary amenorrhoea: lack of menses in a ■ Hypogonadotropic hypogonadism/secondary previously menstruating, non-pregnant female, for hypogonadism: 2 greater than six months – In many cases this may be due to a familial delay in puberty and growth. Other causes include congenital abnormalities Primary amenorrhoea e.g. isolated GnRH deficiency, acquired Key messages: lesions, endocrine disturbance, tumour, systemic illness or eating disorder. ■ The most common cause of primary amenorrhoea in a female with no secondary sexual characteristics ■ Eugonadism: is a constitutional delay in growth and puberty. – Anatomic e.g. congenital absence of the In the first instance, watchful waiting is the most uterus and vagina, intersex
    [Show full text]
  • Effects of Endometriosis on Sleep Quality of Women: Does Life Style
    Youseflu et al. BMC Women's Health (2020) 20:168 https://doi.org/10.1186/s12905-020-01036-z RESEARCH ARTICLE Open Access Effects of endometriosis on sleep quality of women: does life style factor make a difference? Samaneh Youseflu1, Shahideh Jahanian Sadatmahalleh1* , Ghazall Roshanzadeh1, Azadeh Mottaghi2, Anoshirvan Kazemnejad3 and Ashraf Moini4,5,6 Abstract Background: This study aimed to compare the lifestyle factors and SQ between women with and without endometriosis. Also in this essay, the influence of food intake, socio-demographic and clinical characteristics on sleep quality of women with endometriosis was determined. Methods: Of the 156 infertile women approached for the study, 78 women had endometriosis and 78 were included in the control group. At first, each participant completed a checklist including questions about demographics, physical activity, reproductive and menstrual status. SQ was assessed by the Pittsburgh Sleep Quality Index (PSQI). Dietary data were collected using a validated 147-item semi-quantitative FFQ. Results: Irregular menstrual status, menorrhagia, dysmenorrhea, pelvic pain, history of abortion, family history of endometriosis were associated with endometriosis risk (P < 0.05). In women with physical activity more than 3 h per week, high consumption of the dairy product, and fruit endometriosis is less common (P < 0.05). The total PSQI score, and the scores for subjective sleep quality, sleep latency, sleep disturbance domains were significantly different between the two groups (P < 0.05). In women with endometriosis, poor SQ was associated with dysmenorrhea, pelvic pain, dyspareunia, physical activity, and low consumption of the dairy product, fruit, and nut (p < 0.05). Conclusion: In endometriosis women, SQ was lower than healthy individuals.
    [Show full text]
  • Women's Health Concerns
    WOMEN’S HEALTH Natalie Blagowidow. M.D. CONCERNS Gynecologic Issues and Ehlers- Danlos Syndrome/Hypermobility • EDS is associated with a higher frequency of some common gynecologic problems. • EDS is associated with some rare gynecologic disorders. • Pubertal maturation can worsen symptoms associated with EDS. Gynecologic Issues and Ehlers Danlos Syndrome/Hypermobility •Menstruation •Menorrhagia •Dysmenorrhea •Abnormal menstrual cycle •Dyspareunia •Vulvar Disorders •Pelvic Organ Prolapse Puberty and EDS • Symptoms of EDS can become worse with puberty, or can begin at puberty • Hugon-Rodin 2016 series of 386 women with hypermobile type EDS. • 52% who had prepubertal EDS symptoms (chronic pain, fatigue) became worse with puberty. • 17% developed symptoms of EDS with puberty Hormones and EDS • Conflicting data on effects of hormones on connective tissue, joint laxity, and tendons • Estriol decreases the formation of collagen in tendons following exercise • Joint laxity increases during pregnancy • Studies (Non EDS) • Heitz: Increased ACL laxity in luteal phase • Park: Increased knee laxity during ovulation in some, but no difference in hormone levels among all (N=26) Menstrual Cycle Hormonal Changes GYN Issues EDS/HDS:Menorrhagia • Menorrhagia – heavy menstrual bleeding 33-75%, worst in vEDS • Weakness in capillaries and perivascular connective tissue • Abnormal interaction between Von Willebrand factor, platelets and collagen Menstrual cycle : Endometrium HORMONAL CONTRACEPTIVE OPTIONS GYN Menorrhagia: Hormonal Treatment • Oral Contraceptive Pill • Progesterone only medication • Progesterone pill: Norethindrone • Progesterone long acting injection: Depo Provera • Long Acting Implant: Etonorgestrel • IUD with progesterone Hormonal treatment for Menorrhagia •Hernandez and Dietrich, EDS adolescent population in menorrhagia clinic •9/26 fine with first line hormonal medication, often progesterone only pill •15/26 required 2 or more different medications until found effective one.
    [Show full text]